Search

Your search keyword '"Nadia Storti"' showing total 7 results
Start Over Author "Nadia Storti"
7 results on '"Nadia Storti"'

1. A proposal for a comprehensive approach to infections across the surgical pathway

Author

Massimo Sartelli, Leonardo Pagani, Stefania Iannazzo, Maria Luisa Moro, Pierluigi Viale, Angelo Pan, Luca Ansaloni, Federico Coccolini, Marcello Mario D’Errico, Iris Agreiter, Giorgio Amadio Nespola, Francesco Barchiesi, Valeria Benigni, Raffaella Binazzi, Stefano Cappanera, Alessandro Chiodera, Valentina Cola, Daniela Corsi, Francesco Cortese, Massimo Crapis, Francesco Cristini, Alessandro D’Arpino, Belinda De Simone, Stefano Di Bella, Francesco Di Marzo, Abele Donati, Daniele Elisei, Massimo Fantoni, Anna Ferrari, Domitilla Foghetti, Daniela Francisci, Gianni Gattuso, Andrea Giacometti, Guido Cesare Gesuelli, Cristina Marmorale, Enrica Martini, Marcello Meledandri, Rita Murri, Daniela Padrini, Dalia Palmieri, Paola Pauri, Carla Rebagliati, Enrico Ricchizzi, Vittorio Sambri, Anna Maria Schimizzi, Walter Siquini, Loredana Scoccia, Giancarlo Scoppettuolo, Gabriele Sganga, Nadia Storti, Marcello Tavio, Giulio Toccafondi, Fabio Tumietto, Bruno Viaggi, Marco Vivarelli, Cristian Tranà, Melina Raso, Francesco Maria Labricciosa, Sameer Dhingra, and Fausto Catena

Subjects
Antimicrobial resistance, Antimicrobial stewardship, Healthcare-associated infections, Infection control, Multidrug-resistant organisms, Preoperative antibiotic prophylaxis, Surgery, RD1-811, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

Abstract Despite evidence supporting the effectiveness of best practices in infection prevention and management, many healthcare workers fail to implement them and evidence-based practices tend to be underused in routine practice. Prevention and management of infections across the surgical pathway should always focus on collaboration among all healthcare workers sharing knowledge of best practices. To clarify key issues in the prevention and management of infections across the surgical pathway, a multidisciplinary task force of experts convened in Ancona, Italy, on May 31, 2019, for a national meeting. This document represents the executive summary of the final statements approved by the expert panel.

Published
2020
Full Text
View/download PDF

2. Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Author

Giulia Occhipinti, Emanuela Romagnoli, Matteo Santoni, Alessia Cimadamore, Giulia Sorgentoni, Monia Cecati, Matteo Giulietti, Nicola Battelli, Alessandro Maccioni, Nadia Storti, Liang Cheng, Giovanni Principato, Rodolfo Montironi, and Francesco Piva

Subjects
breast cancer, estrogen receptor, cyclin-dependent kinases (CDKs), CDK inhibitors, mechanisms of resistance, Genetics, QH426-470
Abstract

About 75% of all breast cancers are hormone receptor-positive (HR+). However, the efficacy of endocrine therapy is limited due to the high rate of either pre-existing or acquired resistance. In this work we reconstructed the pathways around estrogen receptor (ER), mTOR, and cyclin D in order to compare the effects of CDK4/6 and PI3K/AKT/mTOR inhibitors. A positive feedback loop links mTOR and ER that support each other. We subsequently considered whether a combined or sequential inhibition of CDK4/6 and PI3K/AKT/mTOR could ensure better results. Studies indicate that inhibition of CDK4/6 activates mTOR as an escape mechanism to ensure cell proliferation. In literature, the little evidence dealing with this topic suggests that pre-treatment with mTOR pathway inhibitors could prevent or delay the onset of CDK4/6 inhibitor resistance. Additional studies are needed in order to find biomarkers that can identify patients who will develop this resistance and in whom the sensitivity to CDK4/6 inhibitors can be restored.

Published
2020
Full Text
View/download PDF

4. Treating Prostate Cancer by Antibody-Drug Conjugates

Author

Rodolfo Montironi, Nadia Storti, Alessia Cimadamore, Matteo Santoni, Nicola Battelli, Veronica Mollica, Marina Scarpelli, Francesco Massari, Alessandro Rizzo, Matteo Rosellini, Rosellini M., Santoni M., Mollica V., Rizzo A., Cimadamore A., Scarpelli M., Storti N., Battelli N., Montironi R., and Massari F.

Subjects
Male, Oncology, Immunoconjugates, medicine.medical_treatment, Review, Disease, lcsh:Chemistry, Prostate cancer, Antineoplastic Agents, Immunological, Prostate, Molecular Targeted Therapy, CD46, lcsh:QH301-705.5, Spectroscopy, Clinical Trials as Topic, Disease Management, Standard of Care, General Medicine, Prognosis, prostate cancer, Computer Science Applications, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, medicine.anatomical_structure, B7-H3, Disease Susceptibility, medicine.medical_specialty, Malignancy, Catalysis, Inorganic Chemistry, Breast cancer, Antibody drug conjugate, Internal medicine, Biomarkers, Tumor, medicine, PSMA, Animals, Humans, Physical and Theoretical Chemistry, Molecular Biology, STEAP1, antibody drug conjugates, business.industry, target therapy, Organic Chemistry, Prostatic Neoplasms, Cancer, Immunotherapy, Antibody drug conjugates, Target therapy, TROP2, medicine.disease, lcsh:Biology (General), lcsh:QD1-999, Cancer cell, business
Abstract

Prostate cancer is the most frequent malignancy in the worldwide male population; it is also one of the most common among all the leading cancer-related death causes. In the last two decades, the therapeutic scenario of metastatic castration-resistant prostate cancer has been enriched by the use of chemotherapy and androgen receptor signaling inhibitors (ARSI) and, more recently, by immunotherapy and poly(ADP–ribose) polymerase (PARP) inhibitors. At the same time, several trials have shown the survival benefits related to the administration of novel ARSIs among patients with non-castration-resistant metastatic disease along with nonmetastatic castration-resistant cancer too. Consequently, the therapeutic course of this malignancy has been radically expanded, ensuring survival benefits never seen before. Among the more recently emerging agents, the so-called “antibody–drug conjugates” (ADCs) are noteworthy because of their clinical practice changing outcomes obtained in the management of other malignancies (including breast cancer). The ADCs are novel compounds consisting of cytotoxic agents (also known as the payload) linked to specific antibodies able to recognize antigens expressed over cancer cells’ surfaces. As for prostate cancer, researchers are focusing on STEAP1, TROP2, PSMA, CD46 and B7-H3 as optimal antigens which may be targeted by ADCs. In this paper, we review the pivotal trials that have currently changed the therapeutic approach to prostate cancer, both in the nonmetastatic castration-resistant and metastatic settings. Therefore, we focus on recently published and ongoing trials designed to investigate the clinical activity of ADCs against prostate malignancy, characterizing these agents. Lastly, we briefly discuss some ADCs-related issues with corresponding strategies to overwhelm them, along with future perspectives for these promising novel compounds.

Published
2021

5. A proposal for a comprehensive approach to infections across the surgical pathway

Author

Valentina Cola, Fabio Tumietto, Luca Ansaloni, Enrica Martini, Melina Raso, Iris Agreiter, Stefania Iannazzo, Enrico Ricchizzi, Francesco Barchiesi, Daniela Corsi, Belinda De Simone, Vittorio Sambri, Francesco M. Labricciosa, Massimo Crapis, Gabriele Sganga, Carla Rebagliati, Francesco Cortese, Nadia Storti, Cristian Tranà, Sameer Dhingra, Fausto Catena, Giancarlo Scoppettuolo, Rita Murri, Daniele Elisei, Dalia Palmieri, Giorgio Amadio Nespola, Stefano Cappanera, Daniela Padrini, Bruno Viaggi, Alessandro D’Arpino, Angelo Pan, Leonardo Pagani, Valeria Benigni, Francesco Cristini, Daniela Francisci, Raffaella Binazzi, Francesco Di Marzo, Maria Luisa Moro, Alessandro Chiodera, Pierluigi Viale, Anna Ferrari, Massimo Sartelli, Massimo Fantoni, Cristina Marmorale, Giulio Toccafondi, Anna Maria Schimizzi, Marcello Mario D’Errico, Marcello Meledandri, Loredana Scoccia, Marco Vivarelli, Abele Donati, Stefano Di Bella, Andrea Giacometti, Domitilla Foghetti, Marcello Tavio, Gianni Gattuso, Guido Cesare Gesuelli, Walter Siquini, Paola Pauri, Federico Coccolini, Sartelli, Massimo, Pagani, Leonardo, Iannazzo, Stefania, Luisa Moro, Maria, Viale, Pierluigi, Pan, Angelo, Ansaloni, Luca, Coccolini, Federico, Mario D’Errico, Marcello, Agreiter, Iri, Amadio Nespola, Giorgio, Barchiesi, Francesco, Benigni, Valeria, Binazzi, Raffaella, Cappanera, Stefano, Chiodera, Alessandro, Colaiacolo, Valentina, Corsi, Daniela, POLETTO CORTESE, Francesco, Crapis, Massimo, Cristini, Francesco, D’Arpino, Alessandro, De Simone, Belinda, DI BELLA, Stefano, Di Marzo, Francesco, Donati, Abele, Elisei, Daniele, Fantoni, Massimo, Ferrari, Anna, Foghetti, Domitilla, Francisci, Daniela, Gattuso, Gianni, Giacometti, Andrea, Cesare Gesuelli, Guido, Marmorale, Cristina, Martini, Enrica, Meledandri, Marcello, Murri, Rita, Padrini, Daniela, Palmieri, Dalia, Pauri, Paola, Rebagliati, Carla, Ricchizzi, Enrico, Sambri, Vittorio, Maria Schimizzi, Anna, Siquini, Walter, Scoccia, Loredana, Scoppettuolo, Giancarlo, Sganga, Gabriele, Storti, Nadia, Tavio, Marcello, Toccafondi, Giulio, Tumietto, Fabio, Viaggi, Bruno, Vivarelli, Marco, Tranà, Cristian, Raso, Melina, Maria Labricciosa, Francesco, Dhingra, Sameer, Catena, Fausto, Moro, Maria Luisa, D'Errico, Marcello Mario, Cola, Valentina, Cortese, Francesco, D'Arpino, Alessandro, Di Bella, Stefano, Gesuelli, Guido Cesare, Schimizzi, Anna Maria, and Labricciosa, Francesco Maria

Subjects
Multidrug-resistant organisms, Settore MED/18 - CHIRURGIA GENERALE, Best practice, Preoperative antibiotic prophylaxi, lcsh:Surgery, Preoperative antibiotic prophylaxis, Infection control, Review, [object Object], Routine practice, Antimicrobial stewardship, Healthcare-associated infections, Antimicrobial resistance, 03 medical and health sciences, 0302 clinical medicine, Nursing, Multidisciplinary approach, Health care, Humans, Surgical Wound Infection, Medicine, 030212 general & internal medicine, Healthcare-associated infection, 0303 health sciences, Executive summary, 030306 microbiology, business.industry, Task force, Multidrug-resistant organism, lcsh:Medical emergencies. Critical care. Intensive care. First aid, lcsh:RD1-811, lcsh:RC86-88.9, Anti-Bacterial Agents, Surgical site infections, Emergency Medicine, Surgery, business
Abstract

Despite evidence supporting the effectiveness of best practices in infection prevention and management, many healthcare workers fail to implement them and evidence-based practices tend to be underused in routine practice. Prevention and management of infections across the surgical pathway should always focus on collaboration among all healthcare workers sharing knowledge of best practices. To clarify key issues in the prevention and management of infections across the surgical pathway, a multidisciplinary task force of experts convened in Ancona, Italy, on May 31, 2019, for a national meeting. This document represents the executive summary of the final statements approved by the expert panel.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results